There are several types of immune checkpoints, and drugs targeting three immune checkpoint molecules—PD-1, PD-L1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4)—have been approved in Japan, but not for ovarian cancer. This evidence concerns the gene CD274 and ovarian cancer.